For a premenopausal woman requiring physiologic testosterone replacement, should I use a low‑dose 1 % transdermal testosterone gel instead of the male 2 mg/24‑hour patch?

Should You Use 1% Transdermal Testosterone Gel for Premenopausal Women?

Yes, you can use a 1% transdermal testosterone gel for premenopausal women requiring physiologic testosterone replacement, but you must carefully titrate the dose to achieve premenopausal female physiologic testosterone concentrations—not the male dosing regimen. Both the gel and the 2 mg/24-hour patch are acceptable off-label options, as no FDA-approved female-specific testosterone formulation currently exists 1.

The Core Principle: Physiologic Dosing is Everything

The 2019 Global Consensus Position Statement explicitly states that off-label prescribing of approved male formulations is reasonable, provided hormone concentrations are maintained in the physiologic female range 1. This is the critical distinction—it's not about which formulation you choose, but whether you can reliably achieve and maintain premenopausal female testosterone levels (typically 15-70 ng/dL total testosterone).

Why Either Formulation Can Work

• The 1% gel (such as the 1.62% formulation) delivers 20.25 mg testosterone per pump actuation 2. For women, you would use a fraction of the male dose—typically starting with approximately 5-10 mg daily (roughly 1/4 to 1/2 of one pump actuation).

• The 2 mg/24-hour patch delivers a fixed dose that may be closer to female physiologic needs but offers less flexibility for dose adjustment.

Practical Advantages of the 1% Gel

The gel may offer superior dose titratability for achieving precise female physiologic levels. You can adjust in small increments by using partial pump actuations, whereas the patch comes in fixed doses. However, the gel formulation approved for men delivers testosterone at concentrations designed for male hypogonadism (targeting 350-750 ng/dL) 2, so you must prescribe a much lower dose.

Critical Monitoring Requirements

You must establish baseline and follow-up testosterone monitoring 1:

• Baseline total testosterone before starting therapy
• Repeat level at 3-6 weeks after treatment initiation to ensure you're in the premenopausal female range (not male range)
• Every 6 months thereafter to screen for overuse and assess for signs of androgen excess

Common Pitfall: Supraphysiologic Dosing

The consensus guidelines explicitly warn that preparations resulting in supraphysiologic testosterone concentrations are not recommended 1. Using the standard male dosing of 1% gel (40.5-81 mg daily) would produce dangerously high testosterone levels in women, leading to virilization (hirsutism, acne, voice deepening, clitoromegaly).

Application Technique Modifications for Women

While the FDA label for 1.62% gel specifies application to upper arms and shoulders for men 2, you should limit the application area proportionally when using reduced doses for women. The goal is to apply the small amount needed (5-10 mg) to clean, dry skin with adequate absorption surface.

Secondary Exposure Concerns

The FDA label emphasizes that children and women should avoid contact with unwashed application sites 2. For a female patient using the gel herself, ensure she:

• Washes hands thoroughly after application
• Covers the site with clothing once dry
• Avoids skin-to-skin contact with others until the site is washed

When to Stop Treatment

If no clinical benefit occurs by 6 months, discontinue therapy 1. The only evidence-based indication for testosterone in women is hypoactive sexual desire disorder (HSDD) in postmenopausal women after formal biopsychosocial assessment 1. For premenopausal women, the evidence base is even more limited 3, making careful patient selection and monitoring essential.

The Bottom Line Algorithm

1. Confirm appropriate indication (typically HSDD after comprehensive evaluation)
2. Obtain baseline total testosterone level
3. Start with low-dose 1% gel (approximately 5-10 mg daily, which is 1/4 to 1/2 pump actuation) OR a 2 mg/24-hour patch
4. Recheck testosterone at 3-6 weeks—target premenopausal female range (15-70 ng/dL), NOT male range
5. Adjust dose based on levels and clinical response
6. Monitor every 6 months for efficacy, androgen excess, and testosterone levels
7. Discontinue if no benefit by 6 months

The choice between gel and patch depends on your comfort with dose titration and the patient's preference, but both require the same vigilance about maintaining physiologic female testosterone concentrations 1.